tiprankstipranks
Advertisement
Advertisement

Realbotix Spins Off Commercial Robotics Arm in Stock Deal With Nasdaq-Listed Onconetix

Story Highlights
  • Realbotix is selling its commercial robotics subsidiary to Onconetix in an all-stock deal, gaining a controlling stake and board influence in the Nasdaq-listed company.
  • The transaction separates Realbotix’s commercial and adult consumer businesses, aiming to unlock shareholder value and boost market visibility for its AI humanoid robotics operations.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Meet Samuel – Your Personal Investing Prophet

Tokens.com Corp ( (TSE:XBOT) ) just unveiled an update.

Realbotix Corp. has agreed to sell 100% of its Nevada-based subsidiary Realbotix, LLC to Nasdaq-listed Onconetix, Inc. in an all-stock deal, transferring its robotics engineering teams, AI software group and key patents. The book value of the subsidiary is about $1.8 million, or roughly 18% of Realbotix’s balance sheet, underscoring the strategic nature of the divestiture rather than its purely accounting weight.

Under the terms, Realbotix will receive between 75% and 90% of Onconetix’s fully diluted common stock at closing, based on Onconetix’s net cash position, and will control four of five board seats. After completion, Onconetix will retain its Nasdaq listing, adopt the Realbotix name or a similar brand and position itself as a premier U.S.-made AI humanoid robotics company, potentially giving RealLLC greater capital markets visibility.

The parent company will continue to own and run Abyss Creations as a direct-to-consumer adult-focused hardware and AI business while holding a controlling stake in the Nasdaq-traded robotics entity. Management frames the deal as a deliberate separation of its consumer and commercial operations to let each business focus on its core markets and to create additional value and accessibility for shareholders.

The transaction remains subject to approval by the TSX Venture Exchange and Onconetix shareholders, with closing targeted before the end of the third quarter of 2026. In a related corporate move, Realbotix granted 150,000 stock options to its new chief financial officer, Scott Meyers, reinforcing its leadership structure as it navigates the corporate reorganization.

The most recent analyst rating on (TSE:XBOT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Tokens.com Corp stock, see the TSE:XBOT Stock Forecast page.

More about Tokens.com Corp

Realbotix Corp. is a Nevada-based developer of AI-powered humanoid robots, operating through two main subsidiaries with distinct market focuses. Realbotix, LLC targets commercial clients with embodied AI robots for customer service, healthcare, education, hospitality and entertainment, while Abyss Creations sells advanced silicone-based hardware and AI for companionship and wellness directly to adult consumers.

Average Trading Volume: 267,482

Technical Sentiment Signal: Sell

Current Market Cap: C$73.33M

Learn more about XBOT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1